Gold prices remain near record highs; Fed cut bets prompt weekly gains
Investing.com - Oppenheimer upgraded Boston Scientific (NYSE:BSX) from Perform to Outperform on Monday, setting a price target of $125.00. The medical device giant, currently trading at $107.22 with a market capitalization of $159 billion, has shown robust performance with InvestingPro data indicating a "GREAT" financial health score.
The upgrade positions Boston Scientific as "one of the best large-cap MedTech growth stories," according to Oppenheimer, which cited the company’s disciplined merger and acquisition strategy and strong execution, particularly in its electrophysiology franchise. This assessment is supported by the company’s impressive 21.4% revenue growth over the last twelve months.
Oppenheimer’s price target represents approximately 52 times forward price-to-earnings ratio, compared to the large-cap medical technology sector’s average of about 30 times.
The research firm expects Boston Scientific to achieve 11-13% compound annual growth rate, outpacing the broader large-cap medical technology sector’s approximately 8% growth rate.
Oppenheimer noted that while Boston Scientific is not immune to macroeconomic headwinds, its well-diversified business presents an attractive investment opportunity, with more insights expected after the company’s Investor Day scheduled for September 30.
In other recent news, Boston Scientific Corporation reported a robust second quarter for 2025, with organic revenue growth of 17% year-over-year and a 23% increase in earnings per share. This strong performance has led several analyst firms to raise their price targets for the company. Truist Securities increased its target to $125, citing multiple tailwinds and a broad-based earnings beat, particularly in the PFA and Watchman growth segments. RBC Capital also raised its price target to $125, noting the company’s significant outperformance in end-markets. Meanwhile, Bernstein SocGen Group set a higher price target of $130, highlighting a 17.4% organic sales growth and significant expansion in the electrophysiology division. In other developments, Boston Scientific disclosed that Executive Vice President Jeffrey Mirviss will retire from his role by December 2025 but will continue as a senior advisor for a brief period. Additionally, the FDA has identified a potential high-risk issue with the company’s defibrillation leads, which has been communicated to customers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.